Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXNNASDAQ:BFRINASDAQ:CYCNNASDAQ:PRFX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$8.28+0.8%$7.62$6.51▼$13.27$8.90M1.6293,515 shs3,057 shsBFRIBiofrontera$0.64-4.2%$0.77$0.62▼$2.22$6.04M0.37925,287 shs73,362 shsCYCNCyclerion Therapeutics$3.15-3.0%$2.89$1.27▼$9.47$10.43M1.671.30 million shs3,922 shsPRFXPainReform$1.97+1.0%$2.15$1.68▼$19.20$3.97M0.691.44 million shs35,857 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-4.45%+2.99%+14.45%+10.26%-6.18%BFRIBiofrontera-4.19%-1.52%-21.21%-42.36%-43.88%CYCNCyclerion Therapeutics-2.95%+3.75%+6.92%+11.84%+16.38%PRFXPainReform+1.03%+3.14%-14.35%-37.66%-34.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics1.64 of 5 stars3.53.00.00.00.00.80.0BFRIBiofrontera2.5901 of 5 stars3.55.00.00.01.30.01.3CYCNCyclerion Therapeutics0.8032 of 5 stars0.03.00.00.00.63.30.6PRFXPainReform1.7934 of 5 stars3.04.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00262.54% UpsideBFRIBiofrontera 3.00Buy$2.75329.82% UpsideCYCNCyclerion Therapeutics 0.00N/AN/AN/APRFXPainReform 2.00Hold$8.00306.09% UpsideCurrent Analyst Ratings BreakdownLatest PRFX, CYCN, BFRI, and ADXN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BFRIBiofronteraBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $2.75(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$404.10K21.71N/AN/A$1.20 per share6.90BFRIBiofrontera$37.32M0.16N/AN/A$3.16 per share0.20CYCNCyclerion Therapeutics$2.08M4.87N/AN/A$4.62 per share0.68PRFXPainReformN/AN/AN/AN/A$111.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$11.76M-$0.34N/A∞N/A850.30%-112.43%-77.95%N/ABFRIBiofrontera-$20.13M-$2.26N/AN/AN/A-36.31%-565.73%-96.64%N/ACYCNCyclerion Therapeutics-$5.26M-$1.16N/A∞N/AN/A-55.32%-48.35%8/5/2025 (Estimated)PRFXPainReform-$9.34M-$147.33N/A∞N/AN/A-450.64%-241.33%N/ALatest PRFX, CYCN, BFRI, and ADXN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BFRIBiofrontera-$0.14-$0.47-$0.33-$0.47$10.55 million$8.59 million3/4/2025Q4 2024CYCNCyclerion TherapeuticsN/A$0.22N/A$0.22N/A$1.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A4.594.59BFRIBiofronteraN/A1.530.94CYCNCyclerion TherapeuticsN/A5.075.07PRFXPainReformN/A0.61N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%BFRIBiofrontera10.08%CYCNCyclerion Therapeutics75.62%PRFXPainReform37.28%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%BFRIBiofrontera1.20%CYCNCyclerion Therapeutics34.30%PRFXPainReform34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableBFRIBiofrontera709.45 million7.73 millionNo DataCYCNCyclerion Therapeutics303.21 million1.73 millionNo DataPRFXPainReform42.01 million95,000Not OptionablePRFX, CYCN, BFRI, and ADXN HeadlinesRecent News About These CompaniesPainReform Ltd.May 12, 2025 | barrons.comPainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania’s Largest Solar ProjectsMay 7, 2025 | finance.yahoo.comPainReform Ltd. Launches Strategic Pilot Program with Econergy Renewable Energy Ltd. to Optimize Solar Energy Production using DeepSolar™ PlatformMay 7, 2025 | quiverquant.comPainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar ProjectsMay 7, 2025 | globenewswire.comPainReform Regains Nasdaq Compliance as of April 16, 2025April 17, 2025 | tipranks.comPainReform announces expansion into SEM sectorApril 10, 2025 | markets.businessinsider.comPainReform Shareholders Approve Key Proposals at April MeetingApril 10, 2025 | tipranks.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar’s AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | finance.yahoo.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | globenewswire.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | globenewswire.comPainReform Ltd: PainReform Provides Year-End Business UpdateApril 8, 2025 | finanznachrichten.dePainReform says shareholder equity now exceeds required thresholdApril 8, 2025 | markets.businessinsider.comPainReform Expands into Clean Energy with DeepSolar AcquisitionApril 7, 2025 | tipranks.comPainReform Provides Year-End Business UpdateApril 7, 2025 | globenewswire.comPainReform’s Shareholder Meeting Adjourned Due to Lack of QuorumApril 3, 2025 | tipranks.comPainReform acquires AI solar analytics firm DeepSolarMarch 7, 2025 | uk.investing.comPainReform Ltd: PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar AnalyticsMarch 5, 2025 | finanznachrichten.dePainReform completes acquisition of DeepSolarMarch 5, 2025 | markets.businessinsider.comPainReform Ltd. Completes Acquisition of DeepSolar, Expanding into Clean Energy SectorMarch 5, 2025 | quiverquant.comPainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar AnalyticsMarch 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRFX, CYCN, BFRI, and ADXN Company DescriptionsAddex Therapeutics NASDAQ:ADXN$8.28 +0.07 (+0.79%) Closing price 05/23/2025 03:58 PM EasternExtended Trading$8.11 -0.17 (-2.04%) As of 05/23/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Biofrontera NASDAQ:BFRI$0.64 -0.03 (-4.19%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.64 +0.00 (+0.03%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Cyclerion Therapeutics NASDAQ:CYCN$3.15 -0.10 (-2.95%) Closing price 05/23/2025 03:55 PM EasternExtended Trading$3.23 +0.08 (+2.44%) As of 05/23/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.PainReform NASDAQ:PRFX$1.97 +0.02 (+1.03%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$1.98 +0.01 (+0.51%) As of 05/23/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
